MicroRNAs and prostate cancer

    1. Désirée Bonci1
    1. 1Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanità, viale Regina Elena 299, 00161 Rome, Italy
      2Department of Experimental Oncology, Mediterranean Institute of Oncology, via Penninazzo 7, 95029 Viagrande, Catania, Italy
    1. (Correspondence should be addressed to V Coppola; Email: valeria.coppola{at}iss.it)


    Despite much progress in prostate cancer management, new diagnostic, prognostic and therapeutic tools are needed to predict disease severity, choose among the available treatments and establish more effective therapies for advanced prostate cancer. In the last few years, compelling evidence has documented the role of microRNAs as new broad-spectrum oncogenes or tumour suppressor genes, thus their use as diagnostic, prognostic and therapeutic biomolecules is envisaged. This review extensively and critically summarizes the current knowledge about microRNA deregulation in prostate cancer disease, underlining present limits and future perspectives.

    | Table of Contents